MiR-492 impairs the angiogenic potential of endothelial cells
Article first published online: 26 JUN 2013
© 2013 The Authors. Journal of Cellular and Molecular Medicine Published by Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Journal of Cellular and Molecular Medicine
Volume 17, Issue 8, pages 1006–1015, August 2013
How to Cite
Patella, F., Leucci, E., Evangelista, M., Parker, B., Wen, J., Mercatanti, A., Rizzo, M., Chiavacci, E., Lund, A. H. and Rainaldi, G. (2013), MiR-492 impairs the angiogenic potential of endothelial cells. Journal of Cellular and Molecular Medicine, 17: 1006–1015. doi: 10.1111/jcmm.12085
- Issue published online: 29 AUG 2013
- Article first published online: 26 JUN 2013
- Manuscript Accepted: 13 MAY 2013
- Manuscript Received: 5 DEC 2012
- RSTL-CNR. Grant Number: 783
- EMBO fellowship
- endothelial cell;
Endothelial cells growing in high glucose-containing medium show reduced cell proliferation and in vitro angiogenesis. Evidence suggests that the molecular pathways leading to these cellular responses are controlled by microRNAs, endogenous post-transcriptional regulators of gene expression. To identify the microRNAs and their targeted genes involved in the glucose responses, we performed the miRNA signature of Human Umbelical Vein Endothelial Cells (HUVECs) exposed and unexposed to high glucose. Among differentially expressed microRNAs, we analysed miR-492 and showed that its overexpression was able to reduce proliferation, migration and tube formation of HUVEC. These effects were accompanied by the down-regulation of eNOS, a key regulator of the endothelial cell function. We showed that eNOS was indirectly down-regulated by miR-492 and we discovered that miR-492 was able to bind mRNAs involved in proliferation, migration, tube formation and regulation of eNOS activity and expression. Moreover, we found that miR-492 decreased VEGF expression in HUVEC and impaired in vivo angiogenesis in a tumour xenograft model, suggesting a role also in modulating the secretion of pro-angiogenic factors. Taken together, the data indicate that miR-492 exerts a potent anti-angiogenic activity in endothelial cells and therefore miR-492 seems a promising tool for anti-angiogenic therapy.